Skip to main content

Advertisement

Table 1 Clinicopathologic and histomorphologic features in hepatic steatosis patients

From: Expression patterns of STAT3, ERK and estrogen-receptor α are associated with development and histologic severity of hepatic steatosis: a retrospective study

  NAFLD (n = 18) AFLD (n = 11) Control (n = 38)
Clinical Features    
 Age, mean (range) years 23 ± 6.4 (11–36)a 41 ± 9.5 (23–59)a 61 ± 12.5 (34–89)a
 Sex    
  male 15 (83%) 9 (82%) 11 (29%)
  female 3 (17%) 2 (18%) 27 (71%)
 BMI    
  underweight 0 1 (9%) 2 (5%)
  normal 3 (17%) 6 (55%) 13 (34%)
  overweight 0 2 (18%) 15 (39%)
  obese 15 (83%) 2 (18%) 8 (21%)
Liver Biochemistry    
 AST/ALT ratio    
  ≤2 14 (78%) 6 (55%)
  > 2 4 (22%) 5 (45%)
 AST, median (mean, range) U/L 79 (67, 11~ 192) 67 (105, 21~ 152) 22 (35, 12~ 249)
 ALT, median (mean, range) U/L 84 (124, 11~ 384) 44 (35, 12~ 204) 17 (31, 7~ 252)
 TB, median (mean, range) mg/dL 0.8 (0.9, 0.5~ 12.4) 14 (9, 0.7~ 19.8) 0.7 (0.8, 0.3~ 3.5)
Histomorphological Features    
 Steatosis    None
  5–33% 4 (22%) 2 (18%)  
  > 33–66% 5 (28%) 5 (45%)  
  > 66% 9 (50%) 4 (36%)  
 Lobular inflammation (inflammatory foci/200× field)   None
  < 2 16 (89%) 6 (55%)  
  2–4 2 (11%) 3 (27%)  
  > 4 0 2 (18%)  
 Ballooning degeneration    None
  none 9 (50%) 1 (9%)  
  few 8 (44%) 5 (45%)  
  many 1 (6%) 5 (45%)  
 Fibrosis    None
  none 6 (33%) 1 (9%)  
  perisinusoidal or peripota1 11 (61%) 1 (9%)  
  Perisinusoidal & potal/periportal 1 (6%) 1 (9%)  
  bridging fibrosis 0 3 (27%)  
  cirrhosis 0 5 (45%)  
  1. NAFLD non-alcoholic fatty liver disease
  2. AFLD alcoholic fatty liver disease
  3. Control, 16 cases of biliary cyst and 22 cases of hepatolithiasis
  4. amean ± standard deviation
  5. AST aspartate transaminase
  6. ALT alanine transaminase
  7. TB total bilirubin